Mark Fletcher and Martin Knight, Author at Insights From Our Labs to Yours

Is a different recruitment strategy required to enroll RA biosimilar studies? How to succeed despite increasing volume of RA biosimilar development programs

by Mark Fletcher and Martin Knightupdated on Monday, June 7, 2021Monday, February 17, 2020

Introduction Although a range of regulatory definitions exist, a biosimilar drug is generally defined as \a biological compound that is highly similar to the reference drug, with no clinically meaningful differences in safety, purity and potency.1,2 In addition, biosimilars can be characterized as reducing healthcare costs while maintaining clinical efficacy …

RA biosimilar studies recruitment strategy? How to succeed despite increasing volume of RA biosimilar development programs

by Mark Fletcher and Martin Knightupdated on Monday, June 7, 2021Friday, October 4, 2019

Introduction Although a range of regulatory definitions exist, a biosimilar drug is generally defined as a biological compound that is highly similar to the reference drug, with no clinically meaningful differences in safety, purity and potency.1,2 In addition, biosimilars can be characterized as reducing healthcare costs while maintaining clinical efficacy …

New Mechanisms of Action for Disease Modification in RA

by Mark Fletcher and Martin Knightupdated on Monday, February 17, 2020Thursday, September 14, 2017

Rheumatoid arthritis (RA) is an autoimmune disease primarily affecting the musculoskeletal system with typical symptoms including swollen and painful joints, joint stiffness and loss of function, ultimately leading to disability if untreated. RA also produces significant systemic affects such as fatigue and depression that may appreciably impact quality of life for …